Clinical Trials Logo

Dermatitis, Seborrheic clinical trials

View clinical trials related to Dermatitis, Seborrheic.

Filter by:

NCT ID: NCT04057950 Completed - Dermatitis Clinical Trials

Effects on the Scalp Microbiota of a 1% Selenium Disulfide and 1% Salicylic Acid Shampoo After 2% Ketaconazole Foaming Gel Treatment for Scalp Seborrheic Dermatitis

Start date: June 1, 2019
Phase: N/A
Study type: Interventional

The aim of this study was to investigate the changes in the scalp bacterial and fungal microbiota in subjects afflicted with a scalp seborrheic dermatitis (SSD) during a 2% ketoconazole-based treatment followed by a maintenance phase (1% Selenium Disulfide (SeS2)/1% salicylic acid-based shampoo versus its vehicle).

NCT ID: NCT03830177 Recruiting - Dry Skin; Eczema Clinical Trials

Safety and Efficacy of a Topical Scalp Treatment for Dry Scalp Conditions in Children and Adult

Start date: May 6, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine if a topical treatment for dry scalp conditions, is safe and effective in clinically improving dry scalp conditions. The investigators will additionally examine individuals experience in using the treatment as well as any changes in the scalp microbiome before and after use studying the treatment , the investigators hope to offer children and adults a new, natural way to improve dry scalp conditions.

NCT ID: NCT03807453 Completed - Psoriasis Vulgaris Clinical Trials

Comparison of Scalp Microbiota of the Psoriasis and Seborrheic Dermatitis Patients

Start date: April 25, 2019
Phase:
Study type: Observational

A sterile swap specimen taken from the scalp of the patients with psoriasis vulgaris or seborrheic dermatitis and the volunteer control group will be examined in our study. The examples of the microbiota of the patients will be taken both the lesional scalp and the lesion-free part of the scalp. Then, the microbiota differences between the lesioned scalp and the lesion-free scalp of both groups, and the microbiome differences between the two groups and the control group will be evaluated.

NCT ID: NCT03688971 Recruiting - Clinical trials for Seborrheic Dermatitis

Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis

Start date: October 22, 2018
Phase: Phase 2
Study type: Interventional

To explore the efficacy and pharmacodynamic effects of omiganan topical gel in facial seborrheic dermatitis.

NCT ID: NCT03567980 Completed - Clinical trials for Seborrheic Dermatitis

A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis

Start date: September 1, 2018
Phase: Phase 4
Study type: Interventional

Seborrheic dermatitis is a common and recurrent dermatosis that characteristically involves the scalp, nasolabial folds, eyebrows, glabella, and upper eye lids. It presents as an erythematous, thin scaly patch with a greasy sandpaper texture that varies depending on disease severity. While seborrheic dermatitis most frequently occurs on the face, it can involve other areas of the body especially the chest, abdomen, and axilla. Overall incidence is thought to be between 2-5% of the general population, though this is likely an underestimation. Pruritus is variable, though the signs and symptoms of this disorder are certainly worsened by certain external conditions especially weather, personal perspiration, stress, and poor hygiene. Patients often complain about the red, scaly patches on the face. Antifungal agents are frequently used as monotherapy or in combination regimens in the treatment of seborrheic dermatitis. Topical corticosteroids are often used for their anti-inflammatory effects. Long term use of topical steroids on the face is not a preferred treatment modality due to the risk of striae development and other textural changes that occur over time. Therefore, topical crisaborole may be an alternative given its non-corticosteroid anti-inflammatory action. Crisaborole is a phosphodiesterase-4 (PDE-4) inhibitor that increases intracellular cyclic AMP (cAMP) levels to exert its anti-inflammatory effects. While it has not previously been investigated for its effects in seborrheic dermatitis, further studies evaluating its role in this disease are warranted. Therefore, the investigators propose a proof of concept study using topical crisaborole 2% ointment on the face for 4 weeks to evaluate the anti-inflammatory action of this agent and its utility in the treatment of facial seborrheic dermatitis.

NCT ID: NCT03114111 Completed - Clinical trials for Seborrheic Dermatitis

Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis

Start date: January 2017
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is: 1. To determine the efficacy of photodynamic therapy (PDT) in the treatment of seborrheic dermatitis. 2. To determine how PDT alters the skin microbiome in subjects with seborrheic dermatitis before and after treatment. 3. To determine how PDT alters sebum secretion rates in subjects with seborrheic dermatitis before and after treatment. The researchers hypothesize that PDT will be efficacious in the treatment of seborrheic dermatitis.

NCT ID: NCT02656368 Completed - Clinical trials for Seborrheic Dermatitis

Safety and Efficacy of SEBORRHEAMEDIS Face Cream in Patients With Seborrheic Dermatitis

Start date: January 2015
Phase: N/A
Study type: Interventional

SEBORRHEAMEDIS Face Cream is a barrier-based, non-steroidal cream. The cream includes plant extracts The cream was designed to manage the symptoms of facial Seborrheic dermatitis symptoms such as erythema, scaling and pruritus.

NCT ID: NCT02349854 Completed - Clinical trials for Seborrheic Dermatitis

Neurobiology of the Scalp in Seborrheic Dermatitis

Start date: February 2013
Phase: N/A
Study type: Observational

Seborrheic dermatitis is a common, inflammatory skin condition that causes flaky, white to yellowish scales to form on oily areas such as the scalp or inside the ear. These scales can occur with or without underlying reddened skin. In addition to causing psychological distress, low self esteem, and embarrassment, seborrheic dermatitis is associated with scalp pruritus (itch). Treatment modalities exist to control scalp flaking and itch associated with seborrheic dermatitis, although such therapies often lose efficacy over time. As seborrheic dermatitis is a chronic (life-long) condition, better treatments are needed. The investigators propose to better characterize in subjects with seborrheic dermatitis involving the scalp versus normal scalp controls: (a) the clinical characteristics of the associated itch and (b) the pattern of nerve innervation to the scalp. In this way, the investigators hope to get a comprehensive understanding of the factors causing scalp itch with the aim that this information will create new candidates to which treatment modalities can be designed. At least 12 (up to 20) subjects and similar number of control subjects without disease will have one clinic visit including questionnaires, testing of sensation on the scalp, and biopsy of the scalp.

NCT ID: NCT02004860 Completed - Clinical trials for Severe Seborrheic Dermatitis

Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis

Disease
Start date: January 2014
Phase: Phase 3
Study type: Interventional

Seborrheic dermatitis is a chronic inflammatory dermatological disease, evolving by relapses, affecting mainly the face and scalp. It would be important to have a maintenance treatment for severe forms of seborrheic dermatitis witch is both effective and relatively well tolerated to reduce the frequency of relapses, prolong remissions obtained after attack treatment and reduce the use of topical steroids.

NCT ID: NCT01703793 Completed - Clinical trials for Seborrheic Dermatitis

Safety and Efficacy Study in Subjects With Seborrheic Dermatitis

Start date: September 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if two test products are safe and effective in the treatment of seborrheic dermatitis.